Immunoscintigraphy in cancer care.
Despite numerous publications on the ability of immunoscintigraphy to detect recurrent gastrointestinal and ovarian tumors much earlier than other diagnostic methods currently used in the postoperative follow-up, this method has still not received the clinical recognition it deserves. This is due to multiple factors, but mostly to the lack of well designed multicenter trials intended to assess the large scale efficacy of the method. The cost-benefit approach might be helpful in designing such studies.
Delaloye
A B
AB
Division de Médecine Nucléaire, Centre Hospitalier, Universitaire Vaudois, Lausanne, Switzerland.
Delaloye
B
B
D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003657:Decision Making; D005069:Evaluation Studies as Topic; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging*; D016719:Radioimmunodetection